Bortezomib Plus Rituximab for EBV+ PTLD

Exclusion Criteria

• •Patients receiving any other study agents. Patients already on prophylactic doses of ganciclovir or valganciclovir because of a prior history of CMV infection or because of risk factors for CMV infection are eligible for the study and may continue CMV prophylaxis.
• •Patients with known brain metastases or central nervous system (CNS) involvement of their lymphoma.
• •Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, rituximab, ganciclovir or valgancyclovir.
• •Patients with Grade 2 or greater neuropathy within 14 days before enrollment.
• •Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• •Psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant or breastfeeding women
• •Individuals with a history of malignancy are ineligible except for those outlined in the protocol
• •Known HIV positive individuals
• •Active HBV infection may be included only if they are on appropriate anti-hepatitis B therapy and have an undetectable HBV viral load
• •Patient has received other investigational drugs within 14 days before enrollment
• •Prior bortezomib